JP2023521519A5 - - Google Patents

Info

Publication number
JP2023521519A5
JP2023521519A5 JP2023504152A JP2023504152A JP2023521519A5 JP 2023521519 A5 JP2023521519 A5 JP 2023521519A5 JP 2023504152 A JP2023504152 A JP 2023504152A JP 2023504152 A JP2023504152 A JP 2023504152A JP 2023521519 A5 JP2023521519 A5 JP 2023521519A5
Authority
JP
Japan
Prior art keywords
immune cells
population
cells according
ifnγ
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025906 external-priority patent/WO2021207150A1/en
Publication of JP2023521519A publication Critical patent/JP2023521519A/ja
Publication of JP2023521519A5 publication Critical patent/JP2023521519A5/ja
Pending legal-status Critical Current

Links

JP2023504152A 2020-04-06 2021-04-06 キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞 Pending JP2023521519A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005684P 2020-04-06 2020-04-06
US63/005,684 2020-04-06
PCT/US2021/025906 WO2021207150A1 (en) 2020-04-06 2021-04-06 Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling

Publications (2)

Publication Number Publication Date
JP2023521519A JP2023521519A (ja) 2023-05-24
JP2023521519A5 true JP2023521519A5 (https=) 2024-04-12

Family

ID=78022619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504152A Pending JP2023521519A (ja) 2020-04-06 2021-04-06 キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞

Country Status (10)

Country Link
US (1) US20230149465A1 (https=)
EP (1) EP4132973A4 (https=)
JP (1) JP2023521519A (https=)
KR (1) KR20230019419A (https=)
CN (1) CN115698062A (https=)
AU (1) AU2021251113A1 (https=)
CA (1) CA3173490A1 (https=)
IL (1) IL297034A (https=)
WO (1) WO2021207150A1 (https=)
ZA (1) ZA202210919B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114350665A (zh) * 2022-01-19 2022-04-15 上海优替济生生物医药有限公司 IFN-γ抑制剂及其用途
US20230256065A1 (en) * 2022-02-16 2023-08-17 Elena RUSYN Autologous stem cell vaccine and methods
EP4269432A1 (en) * 2022-04-26 2023-11-01 Universite de Rouen Normandie Production of therapeutic antibodies by the microalgae phaeodactylum tricornutum
KR20250074841A (ko) * 2023-11-20 2025-05-28 (재) 스크립스코리아항체연구원 키메라 항원 수용체를 발현하는 면역 세포 및 트렙타비딘 스캐폴드 항체 유사 단백질을 포함하는 항암용 조성물, 및 이의 용도
CN117965633A (zh) * 2024-04-01 2024-05-03 北京双赢科创生物科技有限公司 一种IFNγ受体敲除的CAR-T细胞的制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
HK1044159A1 (zh) * 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
MX2019004766A (es) * 2016-10-24 2019-09-27 Novimmune Sa Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.
US20200048618A1 (en) * 2017-04-18 2020-02-13 Autolus Limited Cell
US12539308B2 (en) * 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
SG11202007171PA (en) * 2018-02-02 2020-08-28 Univ Pennsylvania Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates
EP3802578A4 (en) * 2018-06-01 2022-03-23 Washington University SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Similar Documents

Publication Publication Date Title
JP2023521519A5 (https=)
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
US20220096544A1 (en) Chemokine expressing cell and use thereof
US20220152101A1 (en) Cellular immunotherapy combination
JP2017513818A5 (https=)
JP2019525956A5 (https=)
JP2021501570A5 (https=)
JP2020513828A5 (https=)
EP3789486A1 (en) Immune effector cell and use thereof
JP2022550899A5 (https=)
EP3822345B1 (en) Genetically engineered cell and application thereof
JP2020517295A5 (https=)
CN110582509A (zh) 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
JP2024534471A5 (https=)
JP2024525492A5 (https=)
JP2024515189A5 (https=)
JP2023548829A5 (https=)
JP2024534417A5 (https=)
WO2021057906A1 (zh) 表达il-15的免疫效应细胞
JP2024536859A5 (https=)
WO2022057941A1 (zh) 表达il-7r结合蛋白的免疫效应细胞
CN112442509A (zh) Cd19-cd20双特异性和双通道car-t及其使用方法
KR20230155521A (ko) 면역 세포 기능의 향상
US20220325241A1 (en) Immune effector cell for co-expressing chemokine receptor